Close Menu

NEW YORK – UK cancer diagnostics and therapies developer Theragnostics today said that it has licensed intellectual property from AstraZeneca covering the use of certain selected radionuclide-labelled Poly (ADP-Ribose) Polymerase inhibitors in the diagnostics field globally.

In addition, Theragnostics has an option to exclusively license the IP for therapeutic uses.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.